Moonlight AI AG, a Swiss startup building image analysis software for clinical-grade diagnostics, has closed a $3.3 million USD Seed round. By converting medical images into actionable insights, Moonlight AI empowers hematologists and pathologists to make faster, more accurate treatment decisions for cancer patients worldwide..

瑞士初创公司 Moonlight AI AG 构建用于临床级诊断的图像分析软件，现已完成 330 万美元的种子轮融资。通过将医学影像转化为可操作的见解，Moonlight AI 赋能血液科医生和病理学家为全球癌症患者做出更快、更准确的治疗决策。

While precision oncology relies on access to genomic data, Next-Generation Sequencing (NGS) remains a bottleneck due to high costs and long turnaround times.

虽然精准肿瘤学依赖于获取基因组数据，但下一代测序（NGS）由于高成本和长周转时间仍然是一个瓶颈。

Moonlight AI

月光AI

solves this by using computer vision to detect genomic biomarkers and complex disease signatures directly from routine imaging of blood and cytology smears.

通过使用计算机视觉直接从血液和细胞学涂片的常规成像中检测基因组生物标志物和复杂疾病特征，解决了这一问题。

'Our technology enables labs to generate actionable, immediate results from slides they already use in their core workflows,' said Christian Ruiz, CEO and co-founder of Moonlight AI. 'By removing the need for expensive hardware or manual processes, we are empowering labs to scale their diagnostic capacity and deliver faster results to patients.'.

“我们的技术使实验室能够从他们核心工作流程中已经在使用的幻灯片生成可操作的、即时的结果，”Moonlight AI首席执行官兼联合创始人克里斯蒂安·鲁伊斯表示。“通过消除对昂贵硬件或手动流程的需求，我们正在赋能实验室扩大诊断能力，并更快地向患者提供结果。”

A primary focus of Moonlight AI’s Seed round is the expansion of their proprietary data library, the first to link whole slide imaging of cytopathology samples with high-quality genomic data. According to CTO and co-founder Nicole H. Romano, “By collaborating with an international consortium of clinical partners, we are curating a dataset that is poised to support model robustness across real-world laboratory settings and patient populations.”.

Moonlight AI 种子轮融资的一个重点是扩展其专有的数据图书馆，这是首个将细胞病理学样本的全切片成像与高质量基因组数据联系起来的数据库。据首席技术官兼联合创始人妮可·H·罗曼诺表示：“通过与国际临床合作伙伴联盟合作，我们正在构建一个数据集，该数据集将有助于在真实世界的实验室环境和患者群体中支持模型的稳健性。”

Moonlight AI will use the funding to expand its team and further develop diagnostic solutions in myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia (CLL), while accelerating the path to commercialization and regulatory approval.

Moonlight AI 将利用这笔资金扩大团队，并进一步开发针对骨髓增生异常综合征 (MDS)、非小细胞肺癌和慢性淋巴细胞白血病 (CLL) 的诊断解决方案，同时加快商业化进程和监管审批。

According to Dr. Stefan Habringer, Chief Medical Officer and co-founder of Moonlight AI, “The success of AI‑based diagnostics depends fundamentally on the quality and diversity of clinical data. We are therefore opening our consortium to additional hospitals and laboratories interested in shaping the next generation of diagnostics.”.

据 Moonlight AI 首席医疗官兼联合创始人斯特凡·哈布林格博士称：“基于人工智能的诊断的成功从根本上取决于临床数据的质量和多样性。因此，我们正在向有兴趣塑造下一代诊断技术的其他医院和实验室开放我们的联盟。”

The investment was co-led by

该投资由以下公司共同领投

Lotus One Investment

莲花一号投资

(Singapore),

（新加坡），

VP Venture Partners

副总裁风险投资伙伴

(Switzerland), and

（瑞士），以及

MEDIN Fund

医疗创新基金

(Tunisia), with participation from

（突尼斯），参与方包括

N&V Capital

N&V资本

(Liechtenstein) and existing investor

（列支敦士登）和现有投资者

QAI Ventures

QAI风险投资公司

(Switzerland).

（瑞士）。

Alexandra Beckstein, QAI Ventures: “Having backed Moonlight AI early, it’s encouraging to see the team reach this milestone. We look forward to seeing their continued progress toward clinical adoption and scale.”

亚历山德拉·贝克斯坦，QAI Ventures：“我们很早就支持了Moonlight AI，看到团队达到这一里程碑令人鼓舞。我们期待他们继续在临床应用和规模化方面取得进展。”

Asmita Dwivedi, Lotus One Investment Pte. Ltd.: “We invested with strong conviction in the founders, who combine deep clinical and scientific expertise with a clear sense of purpose. They are addressing a critical gap in disease detection, with the potential to make high-quality diagnostics more affordable and widely available.”.

“Asmita Dwivedi，莲花一号投资有限公司：‘我们怀着强烈的信念投资于这些创始人，他们将深厚的临床和科学专业知识与明确的目标感结合在一起。他们正在解决疾病检测中的一个关键空白，有潜力使高质量诊断变得更实惠且广泛可用。’”

Ruth Ketley, VP Venture Partners: “Moonlight AI is addressing a real bottleneck in clinical diagnostics. The team has the potential to meaningfully improve laboratory efficiency and patient care.”

露丝·凯特利，VP风险合伙人：“Moonlight AI正在解决临床诊断中的一个真正瓶颈。该团队有潜力显著提高实验室效率和患者护理水平。”

Ghazi Ben Othman, MEDIN Fund: “We are excited to be backing a world class scientific team that is developing bleeding-edge technology to bring relief to millions of cancer patients.”

加齐·本·奥特曼，MEDIN基金：“我们非常激动能够支持这个正在开发尖端技术的世界级科学团队，为数百万癌症患者带来福音。”

(Press release / SK)

（新闻稿 / SK）

Photo: Moonlight AI team LR: Christian Ruiz (CEO), Nicole H. Romano (CTO), Stefan Habringer (CMO)

照片：月光AI团队 LR：克里斯蒂安·鲁伊斯（首席执行官），妮可·H·罗曼诺（首席技术官），斯特凡·哈布林格（首席营销官）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送